Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
Learn more about this landmark case that underscores the critical importance of patient safety rules and proper care.
All Specialties October 18th 2023
To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.
Neurology June 21st 2022
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS